FDA Broadens Pitolisant Label - Poll - MDSpire

FDA Broadens Pitolisant Label

The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 2 min

Share

Original Source(s)

FDA Broadens Pitolisant Label

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Pediatric Bowhunter Syndrome: What Do We Know?

Bowhunter syndrome (BHS) is a rare but important cause of posterior circulation stroke in children, resulting from vertebral artery compression during head rotation.

  • June 19, 2026

  • 1 min
Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"

Why Practices Join Hospital Systems

Interviews with hospital leaders and employed physicians highlighted financial pressures, perceived care-integration benefits, and unresolved operational tensions following acquisition.